Effectiveness of a reliever-based Digital System on asthma control

Le résumé fourni par la source

Introduction: The Digital System (DS) comprises the Digihaler® integrated inhaler (albuterol 90µg) that transmits data wirelessly to a mobile application, which synchronizes with a Digital Health Platform to store and transfer data to a web-based dashboard. This allows patients (pts) and clinicians to track and review reliever inhaler usage and inhalation quality, to aid clinical decision making. Aims: To evaluate asthma control as measured by the Asthma Control Test (ACT); DS vs standard of care (SoC). Methods: 333 eligible pts were randomized to DS (N=167) or SoC (N=166) for 12‑weeks. It was expected that the dashboard would be checked ≥1 a week for each pts inhalation data (usage, inhalation quality parameters). Primary outcome (N=316): proportion of pts achieving meaningful improvement, (ACT score ≥20 at week 12, or increase ≥3 units from baseline). Bayesian statistical analysis provided a posterior probability distribution for odds ratios with corresponding credible intervals. Results: There was an 82.5% probability that pts using DS would have greater odds of achieving improvements in asthma control vs SoC after 3 months. Mean odds ratio of improvement in asthma control were 1.29 times greater (29% greater) in pts using DS vs SoC. Conclusions: After 3 months, pts using the DS had greater odds of clinically meaningful improvements in asthma control vs SoC. Further investigation of the potential of the DS to help improve asthma management is warranted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.